Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book comprises a series of chapters from experts in the field of diagnosis and treatment of myeloid leukemias from all over the world, including America, Europe, Africa and Asia. It contains both reviews on clinical aspects of acute (AML) and chronic myeloid leukemias (CML) and original publications covering specific clinical aspects of these important diseases. Covering the specifics of myeloid leukemia epidemiology, diagnosis, risk stratification and management by authors from different parts of the world, this book will be of interest to experienced hematologists as well as physicians in training and students from all around the globe.

Myeloid leukemia. --- Granulocytic leukemia --- Myelogenous leukemia --- Myelocytic leukemia --- Bone marrow --- Nonlymphoid leukemia --- Diseases --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Virus diseases --- Myelocytic leukemia --- Hematopoietic stem cell disorders --- Bone marrow cells

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book offers a remarkable coverage of myeloid leukemia from diagnosis to treatment. It provides an updated and new vision of this multifaceted disease, regrouping a variety of myeloid disorders. To ensure the high quality of this book, important insights are included and rigorously discussed in a simple and authentic way. This book is a relevant source of knowledge, very useful for researchers, medical doctors, nurses, students and individuals interested in this complex disease.

Myeloid leukemia. --- Granulocytic leukemia --- Myelogenous leukemia --- Myelocytic leukemia --- Bone marrow --- Nonlymphoid leukemia --- Diseases --- Medicine --- Hematological Oncology --- Hematology --- Health Sciences

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib. .

Medicine. --- Hematology. --- Medicine & Public Health. --- Chronic myeloid leukemia. --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Chronic leukemia --- Myeloid leukemia --- Haematology --- Internal medicine --- Blood --- Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria. .

Chronic myeloid leukemia --- Chronic granulocytic leukemia --- Chronic myelocytic leukemia --- Chronic myelogenous leukemia --- CML (Disease) --- Chronic leukemia --- Myeloid leukemia --- Hematology. --- Oncology  . --- Oncology. --- Pharmacotherapy. --- Tumors --- Haematology --- Internal medicine --- Blood --- Diseases --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Pharmacology